Stay updated on Clinical Trial: Delandistrogene in Duchenne Muscular Dystrophy

Sign up to get notified when there's something new on the Clinical Trial: Delandistrogene in Duchenne Muscular Dystrophy page.
Latest website image capture
Clouds background image

Latest updates to the Clinical Trial: Delandistrogene in Duchenne Muscular Dystrophy page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-02-24T21:26:37.000Z thumbnail image
  5. Check
    33 days ago
    No Change Detected
  6. Check
    40 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    1%
    Check dated 2025-02-10T13:42:45.000Z thumbnail image
  7. Check
    47 days ago
    Change Detected
    Summary
    The website has been updated from version v2.14.1 to v2.14.2.
    Difference
    0.1%
    Check dated 2025-02-03T10:00:05.000Z thumbnail image
  8. Check
    62 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.0 to 2.14.1.
    Difference
    0.1%
    Check dated 2025-01-20T00:36:33.000Z thumbnail image
  9. Check
    69 days ago
    Change Detected
    Summary
    The website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant change in this functionality.
    Difference
    0.2%
    Check dated 2025-01-12T19:22:15.000Z thumbnail image
  10. Check
    98 days ago
    Change Detected
    Summary
    The latest updates include the posting of results for various assessments related to motor function and dystrophin protein expression in participants with Duchenne Muscular Dystrophy, highlighting significant changes from baseline to Week 52, along with a summary of treatment emergent adverse events.
    Difference
    55%
    Check dated 2024-12-14T23:01:34.000Z thumbnail image

Stay in the know with updates to Clinical Trial: Delandistrogene in Duchenne Muscular Dystrophy

Enter your email address, and we'll notify you when there's something new on the Clinical Trial: Delandistrogene in Duchenne Muscular Dystrophy page.